Eli Lilly Keeps Pulling Ahead—Can Novo Nordisk Catch Up? Eli Lilly leads Novo Nordisk in GLP-1 market share and analyst sentiment, while Novo pins hopes on its CagriSema catalyst and pipeline to offset patent-cliff pressure and lawsuits.
Why Viking Therapeutics Stock Skyrocketed on Tuesday The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.
Novo Nordisk Has a Fresh New Name -- but It Still Faces the Same Old Problems Novo Nordisk is dealing with headwinds, but was its name really one of the big problems?
Novo Nordisk Targets Five Multi-Blockbusters by 2030 as Oral Wegovy Gains Traction Novo Nordisk A/S (
NYSE:NVO ) outlined an updated strategy at its Capital Markets Day centered on diabetes and obesity, expansion into blood and endocrine disorders, liver disease and cardiovascular conditions, and a growing focus on consumer-facing prescription medicine channels.
The company said it
Why Novo Nordisk Stock Just Crashed No one expects a lot of growth from Novo Nordisk anymore -- not even Novo Nordisk itself.
Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. The weight loss market is highly competitive, but Viking only needs to carve out a small niche in it with VK2735 in order to generate significant value for investors.
This Trend is Excellent News for Eli Lilly and Its Investors Eli Lilly and Novo Nordisk are vying for a new part of the weight loss drug market.
Where Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded? The company is still looking to bounce back after the beating it took in recent years.
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 These stocks have been struggling lately, but they could be underrated buys in the long run.
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind.
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? AbbVie's diversified portfolio faces patent headwinds, while Novo Nordisk dominates a faster-growing market, but one trades at a steeper valuation.
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.
3 of the Best Growth Stocks to Buy for Less Than $100 Right Now Netflix, Uber, and Novo Nordisk are all excellent, undervalued stocks to buy today.
Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock? The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.
Viking Therapeutics Trades Well Below Its Wall Street Targets. Here's the Skeptics' Case. Investors always need to appreciate risk before buying into any clinical-stage biopharmaceutical company.
Should Eli Lilly Investors Be Worried About a Threat From Amylyx? Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly? Novo Nordisk is leaning into convenience as it tries to regain its lead in the GLP-1 weight-loss space.
